Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis AMERICAN JOURNAL OF HEMATOLOGY O'Brien, S. M., Byrd, J. C., Hillmen, P., Coutre, S., Brown, J. R., Barr, P. M., Barrientos, J. C., Devereux, S., Robak, T., Reddy, N. M., Kipps, T. J., Tedeschi, A., Cynnbalista, F., Ghia, P., Chang, S., Ninomoto, J., James, D. F., Burger, J. A. 2019; 94 (5): 554–62
View details for DOI 10.1002/ajh.25436
View details for Web of Science ID 000468303900006